ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 103 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $275,000 | -8.3% | 18,965 | +26.1% | 0.06% | 0.0% |
Q2 2018 | $300,000 | +23.0% | 15,044 | +51.8% | 0.06% | +43.9% |
Q4 2017 | $244,000 | -45.7% | 9,908 | -44.3% | 0.04% | -36.9% |
Q3 2017 | $449,000 | -11.3% | 17,791 | -4.7% | 0.06% | -4.4% |
Q2 2017 | $506,000 | +25.2% | 18,662 | +37.8% | 0.07% | +25.9% |
Q1 2017 | $404,000 | +82.0% | 13,546 | +65.5% | 0.05% | +80.0% |
Q4 2016 | $222,000 | – | 8,183 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |